On March 30, 2026, United Therapeutics reported that its 598-patient phase 3 TETON-1 trial of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, showing a 130.1 mL advantage in forced vital capacity over placebo at 52 weeks and reduced risk of clinical worsening, with consistent benefits across subgroups and no new safety signals. Integrated analyses of TETON-1 and TETON-2 confirmed significant treatment effects on lung function and key secondary outcomes, and the company said the unprecedented IPF data from TETON alongside its recent ralinepag success mark an inflection point for growth as it prepares an FDA filing to add IPF to Tyvaso’s label, potentially reshaping the treatment landscape for this underserved disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.